4basebio Q3 Revenues Down 5 Percent, Firm Approves Spinoff of DNA Manufacturing Business

Nov 12, 2020

|

NEW YORK — 4basebio on Thursday posted a 5 percent year-over-year decline in revenues for the third quarter, reflecting a reduction in US sales following the closure of the company's San Diego site. In addition, it has approved the spinoff of its DNA manufacturing business.

For the three-month period ended September 30, 4basebio's revenues fell to €289,000 ($340,800) from €305,000 a year earlier, as a bulk sale of enzymes from the company's Spanish operations partially offset the lower US sales.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Jan

26

Featured Webinar

Panel Discussion: Genotyping by Sequencing for Novel SNP Discovery with Less Common Genomes

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Feb

11

Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb

25

Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Menu

4basebio Q3 Revenues Down 5 Percent, Firm Approves Spinoff of DNA Manufacturing Business

To read the full story....

Breaking News

Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

Bionano Genomics to Raise $200M in Public Stock Offering

CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

Interpace Bio Q3 Revenues Rise 6 Percent

Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

Predictive Oncology Prices $2.2M Direct Offering

The Scan

Boosting Viral Surveillance

California Strain

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

Lander Nominated for Science Advisor

Panel Discussion: Genotyping by Sequencing for Novel SNP Discovery with Less Common Genomes

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsorships